RLMD
RELMADA THERAPEUTICS, INC.
Key Financials
Operating Income
$-59100200
↑ 29.6%
Net Income
$-57385163
↑ 28.3%
Gross Profit
$3235
↑ 196.0%
Revenue
$13070
↑ 154.8%
EPS (Diluted)
$-1.45
↑ 45.3%
Total Assets
$94.0M
↑ 105.2%
Total Liabilities
$7.5M
↓ 27.2%
Shareholders' Equity
$86.5M
↑ 143.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| 8-K | 8/6/2026 | View on SEC |
| 10-Q | 8/6/2026 | View on SEC |
| SCHEDULE 13G | 7/29/2026 | View on SEC |
| 8-K | 7/28/2026 | View on SEC |
| SCHEDULE 13G | 6/22/2026 | View on SEC |
| S-8 | 6/18/2026 | View on SEC |
| SCHEDULE 13G | 6/9/2026 | View on SEC |
| 8-K | 5/28/2026 | View on SEC |
| S-3ASR | 5/13/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | RLMD |
| Company Name | RELMADA THERAPEUTICS, INC. |
| CIK | 1553643 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | NV |
| Phone | 646 876 3459 |